Protective effects of bendazac lysine on early experimental diabetic nephropathy in rats

Acta Pharmacologica Sinica

Volumn 26, Issue 6, 2005, Pages 721-728

  Yin, Xiao Xing ^a   Zhang, Yin Di ^a   Shen, Jian Ping ^a   Wu, Hai Wei ^a   Zhu, Xiang ^a   Li, Li Min ^a   Qiu, Jun ^a   Jiang, Shao Jun ^b   Zheng, Xiao Gang ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

Author keywords

Bendazac lysine; Blood glucose; Diabetic nephropathies; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; ALDOSE REDUCTASE INHIBITOR; BENDAZAC LYSINE; EPALRESTAT; GLUCOSE; LAMININ; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTHROPOMETRY; ANTIOXIDANT ACTIVITY; ARTICLE; AUTONOMIC DYSFUNCTION; BODY WEIGHT; CACHEXIA; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVITY; EXPERIMENTAL DIABETIC NEPHROPATHY; EXPERIMENTAL MODEL; GENE EXPRESSION; GLOMERULUS; GLOMERULUS BASEMENT MEMBRANE; GLUCOSE BLOOD LEVEL; HYPOPRAXIA; KIDNEY CORTEX; KIDNEY INDEX; KIDNEY MASS; LOW DRUG DOSE; MALE; MESANGIUM; MICROALBUMINURIA; NONHUMAN; POLYURIA; RAT; RENAL PROTECTION; STREPTOZOCIN DIABETES; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ALDEHYDE REDUCTASE; ANIMALS; DIABETIC NEPHROPATHIES; ERYTHROCYTES; GLOMERULAR MESANGIUM; GLYCOSYLATION END PRODUCTS, ADVANCED; INDAZOLES; KIDNEY; LAMININ; MALE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 20444375855     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2005.00111.x     Document Type: Article

References (27)

1. Catherwood MA, Powell LA, Anderson P, McMaster D, Sharpe PC, Trimble ER. Glucose-induced oxidative stress in mesangial cells. Kidney Int 2002; 61: 599-608.
2. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001; 27: 535-42.
3. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001; 44: 1957-72.
4. Sharma K, McGowan Tracy A. TGF-β in diabetic kidney: role of novel signaling pathways. Cytokine Growth Factor Rev 2000; 11: 115-23.
5. Liu BC, Chen Q, Luo DD, Sun J, Phillips AO, Ruan XZ, et al. Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats. Acta Pharmacol Sin 2003; 24: 67-73.
6. Balfour JA, Clissold SP. Bendazac lysine: a review of its pharmacological properties and therapeutic potential in the management of cataracts. Drugs 1990; 39: 575-96.
7. Inliano G, Menzion M, Apponi-Battini G, Costagliola C. Inhibition of rat lens aldose reductase by bandazac-L-lysine salt. Enzyme 1989; 42: 235-7.
8. Schmut O, Hofmann H. Studies on the activity of bendalina (bendazac L-lysine salt) as a scavenger of hydroxyl and superoxide radials. Wien Klin Wochenschr 1985; 97: 819-22.
9. Marques C, Ramalho JS, Pereira P, Mota MC. Bendazac decreases in vitro glycation of human lens crystalline. Decrease of in vitro protein glycation by bendazac. Doc Ophthalmol 1995; 90: 395-404.
10. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993; 84: 407-12.
11. Das B, Srivastava SK. Purification and properties of aldose reductase and aldehyde reductase II from human erythrocyte. Arch Biochem Biophy 1985; 238: 670-9.
12. Kaneto H, Morrissey J, Klahr S. Increased expression of TGF-β1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 1993; 44: 313-21.
13. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Lefebvre PJ. Metabolic control may influence the increased superoxide generation in diabetic serum. Diabetic Med 1991; 8: 540-2.
14. Schmut, Fellinger C, Hofmann H. Bendazac lysine: a protective substance against oxygen-free radicals. In: D'Ermo F. Recent developments in the pharmacological treatment of cataract. Amsterdam: Kugler Publications; 1987. p 69-72.
15. ε-(carboxymethyl) lysine in human tissues in diabetes and aging. J Clin Invest 1997; 99: 457-68.
16. Ihm SH, Yoo HJ, Park SW, Ihm J. Effect of aminiguanidine on lipid peroxidation in streptozotocin-induced diabetic rats. Metabolism 1999; 48: 1141-5.
17. Min C, Kang E, Yu SK, Shinn SH, Kim YS. Advanced glycation end products induce apoptosis and procoagulant activity in cultured human umbilical vein endothelial cells. Diab Res Clin Pract 1999; 46: 197-202.
18. Lewis BS, Harding JJ. The major metabolite of bendazac inhibits the glycosylation of soluble lens proteins: a possible mechanism for a delay in cataractogenesis. Exp Eye Res 1988; 47: 217-25.
19. Lewis BS, Rixon KC, Harding JJ. Bendazac prevents cyanate binging to soluble lens proteins and cyanate-induced phase-separation opacities in vitro: a possible mechanism by which bendazac could delay cataract. Exp Eye Res 1986; 43: 973-9.
20. Jandeleit-Dahm K, Cao ZM, Cox AJ, Kelly DJ, Gilbert RE, Cooper ME. Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int 1999; 56 (Suppl 71): S31-6.
21. Montero A, Munger KA, Khan RZ, Valdivielso JM, Morrow JD, Guasch A, et al. F-2-isoprostanes mediate high glucose-induced TGF-beta synthesis and glomerular proteinuria in experimental type I diabetes. Kidney Int 2000; 58: 1963-72.
22. Yin XX, Zhang YD, Wu HW, Zhu X, Zheng XG, Jiang SJ, et al. Protective effects of Astragalus Sapoonin I on early stage of diabetic nephropathy in rats. J Pharmacol Sci 2004; 95: 256-66.
23. Greene DA, Lattimer SA, Sima AAF. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complicatins. N Engl J Med 1987; 316: 599-606.
24. Ishii H, Tada H, Isogai S. An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-beta and protein kinase C activity in cultured human mesangial cells. Diabetologia 1998; 41: 362-4.
25. Suzuki K, Kawamura T, Sakakibara F, Sasaki H, Sano T, Sakamoto N, et al. Effect of aldose reductase inhibitors on glucose-induced changes in sorbitol and myo-inositol metabolism in human neutrophils. Diabet Med 1999; 16: 67-73.
26. Hamada Y, Nakamura J, Naruse K, Komori T, Kato K, Kasuya Y, et al. Epalrestat, an aldose reductase inhibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care 2000; 23: 1539-44.
27. Nakayama M, Nakamura J, Hamada Y, Chaya S, Mizubayashi R, Yasuda Y, et al. Aldose reductase inhibition ameliorates papillary light reflex and F-wave latency in patients with mild diabetic neuropathy. Diabetes Care 2001; 24: 1093-8.